CHICAGO, June 5 /PRNewswire-USNewswire/ —
Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that
shows nitrogen-containing bisphosphonates, therapeutic agents used
to promote bone health and inhibit resorption, may cause a slightly
poorer survival rate in post-menopausal women with early stage
breast cancer who take them for their anti-osteoporosis properties.
The findings were announced today at the 2010 American Society of
Clinical Oncology Annual Meeting.
(Logo: http://photos.prnewswire.com/prnh/20071106/KARMANOSLOGO
)
Preclinical data suggests that bisphosphonates exhibit
anti-tumor activity. Karmanos researchers, led by Zeina Nahleh,
M.D., F.A.C.P., co-leader of the Breast Cancer Multidisciplinary
Team and assistant professor of Internal Medicine at Karmanos and
Wayne State University School of
Medicine, conducted a two-year retrospective study that extracted
data from the Metropolitan Detroit Cancer Surveillance System, a
Surveillance, Epidemiology, and End Results registry.
A total of 696 patients 50 years and older with Stage I, II and
III invasive breast cancer, diagnosed between 2000 and 2003, were
included in the study. Ninety-seven women, or 14 percent of study
participants, used nitrogen-containing bisphosphonates. The
difference in overall survival between bisphosphonate users and
non-users was not statistically significant at three years, with
overall survival equating to 94 percent of bisphosphonate users and
88 percent of non-use
‘/>”/>
